Contraindicated. Coadministration of doravirine with a robust CYP3A inducer may possibly lessen doravirine plasma concentrations and/or effects. Likely for loss of virologic reaction and feasible resistance to doravirine. pentobarbital and olopatadine intranasal both increase sedation. Stay clear